XÁC ĐỊNH TẦN SUẤT PHÂN LẬP VÀ MỨC ĐỘ NHẠY CẢM VỚI KHÁNG SINH CỦA ESCHERICHIA COLI PHÂN LẬP TỪ CÁC BỆNH PHẨM KHÁC NHAU TẠI MEDLATEC (2022 - 2024)

Abstract

Objectives: To determine the prevalence and antibiotic susceptibility profiles of Escherichia coli strains isolated from various clinical specimens at Medlatec (2022–2024). Methods: A cross-sectional descriptive study was conducted on 34,983 different clinical specimens collected between January 2022 and December 2024 at the Laboratory Center of the Medlatec Healthcare System (Vietnam). E. coli was isolated from clinical specimens by culture on blood agar. Species identification and antibiotic susceptibility testing were performed using the Vitek 2 Compact system. Antimicrobial susceptibility results were interpreted according to the M100 guidelines of the Clinical and Laboratory Standards Institute (CLSI, USA). Escherichia coli ATCC 25922 was used as the reference strain. Results: Among the 34,983 clinical specimens analyzed, 2,329 samples were positive for E. coli, accounting for 6.7%. E. coli exhibited high resistance rates to ampicillin (86.6%), trimethoprim/sulfamethoxazole (69.8%), and ciprofloxacin (>65%). In contrast, E. coli remained highly susceptible to carbapenems, amikacin, and fosfomycin, with susceptibility rates exceeding 96%. The prevalence of multidrug resistance and extensive drug resistance ranged from 51.5% to 57.4% and from 8.3% to 17.6%, respectively. Conclusion: E. coli exhibits high resistance to many commonly used antibiotics. The widespread occurrence of multidrug-resistant and extensively drug-resistant E. coli underscores the urgent need to strengthen surveillance activities and antimicrobial stewardship for this pathogen